Cellectis (CLLS) EPS (Basic) Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -100.00% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -79.34% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 61.11% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3,856.63% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -7.78% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,207.14% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -425.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -425.30% |
| Dec 31, 2025 | -91.36% |
| Sep 30, 2025 | 308.83% |
| Dec 31, 2024 | 98.59% |
| Sep 30, 2024 | 100.25% |
| Dec 31, 2023 | -973.08% |
| Sep 30, 2023 | -15,887.93% |
| Jun 30, 2023 | -2,058,593.53% |
| Mar 31, 2023 | 38.49% |
| Dec 31, 2022 | 64.30% |
| Sep 30, 2022 | 86.52% |
| Jun 30, 2022 | 99.92% |
| Mar 31, 2022 | 69.23% |
| Dec 31, 2021 | 80.61% |
| Sep 30, 2021 | -35.62% |
| Jun 30, 2021 | -6.58% |
| Mar 31, 2021 | -236.45% |
| Dec 31, 2020 | -0.99% |
| Sep 30, 2020 | -10.06% |
| Jun 30, 2020 | 6.03% |
| Mar 31, 2020 | 162.29% |
| Dec 31, 2019 | -31.43% |
| Sep 30, 2019 | 7.83% |
| Jun 30, 2019 | -61.78% |
| Mar 31, 2019 | 20.29% |
| Dec 31, 2018 | 10.66% |
| Sep 30, 2018 | 3.81% |
| Jun 30, 2018 | 29.05% |
| Mar 31, 2018 | 6.20% |
| Dec 31, 2017 | -44.93% |
| Sep 30, 2017 | -48.90% |
| Jun 30, 2017 | -95.13% |
| Mar 31, 2017 | 3.51% |
| Jun 30, 2016 | 18.04% |